Cargando…
TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells
Chronic myeloid leukemia (CML) is a hematological disease, and imatinib (IM) resistance represents a major problem for its clinical treatment. In the present study, the role of tribbles pseudokinase 2 (TRIB2) in IM resistance of CML and the possible mechanism were investigated. It was found that TRI...
Autores principales: | Sun, Hang, Li, Youjie, Wang, Xiao, Zhou, Xue, Rong, Simin, Liang, Dongmin, Sun, Guangbin, Cao, Huizhen, Sun, Hongfang, Wang, Ranran, Yan, Yunfei, Xie, Shuyang, Sun, Yunxiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973951/ https://www.ncbi.nlm.nih.gov/pubmed/35302171 http://dx.doi.org/10.3892/ijo.2022.5339 |
Ejemplares similares
-
NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia
por: Wang, Xiao, et al.
Publicado: (2023) -
Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023) -
MiR‐138‐5p suppresses the progression of lung cancer by targeting SNIP1
por: Wu, Jiaen, et al.
Publicado: (2023) -
RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
por: Hao, Ruimin, et al.
Publicado: (2021) -
Anticancer roles of let-7f-1-3p in non-small cell lung cancer via direct targeting of integrin β1
por: Yang, Yanan, et al.
Publicado: (2021)